The spectacular performance of biopharma companies in the public markets last year has carried over into optimism for early 2014. Will the boom continue?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Annette Grimaldi is a managing director at BMO Capital Markets in New York.
Rights and permissions
About this article
Cite this article
Grimaldi, A. From the analyst's couch: The outlook for biotech exits. Nat Biotechnol 32, 227–228 (2014). https://doi.org/10.1038/nbt.2852
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2852
